Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lymphatic Diseases 1Immunoproliferative Disorders 1Hematologic Diseases 1

Interventions

Rituximab 4Etoposide 3Cyclophosphamide 3cobomarsen 2Vincristine 2Prednisone 2Ifosfamide 2Doxorubicin 2Carboplatin 2Brentuximab Vedotin 2ponatinib 1pomalidomide 1ibritumomab tiuxetan 1fludarabine 1dacetuzumab 1Vorinostat 1Melphalan 1Imatinib Mesylate 1Everolimus 1DTRMWXHS-12 1Cytarabine 1Carmustine 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphatic Diseases × dacetuzumab × Clear all
NCT00529503 2015-02-25

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Seagen Inc.

Phase 2 Terminated
151 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡